Biocon Limited — Important, 18-06-2025: General Updates

Biocon has announced a board meeting to consider financial results for the quarter and half-year. CRISIL has reaffirmed its credit ratings at AA+/Stable for long term and A1+ for short term on Rs 250 Cr bank facilities, reflecting Biocon’s strong biopharma market position, diversified revenue streams (biosimilars 58%, generics 19%, research services 23%), and robust biosimilar pipeline. Fiscal 2025 revenue grew 3% to Rs 15,262 Cr with Ebitda margin at 20.7%. Debt is expected to ease with a planned Rs 4,500 Cr fundraise and recent refinancing, supporting medium-term deleveraging and margin improvement. New product launches and capacity expansions underpin growth prospects.